Last Update: Oct 01, 2024
An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (VICTORION-PEDS-OLE)
ClinicalTrials.gov Identifier:
Novartis Reference Number:CKJX839C12001B
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this open-label, single arm, multicenter extension study is to evaluate
the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who
have completed the ORION-16 or ORION-13 studies. This is an open-label, single arm, multicenter study designed to evaluate long-term
safety and tolerability of inclisiran. In addition, the study will provide participants
the opportunity to have continued access to treatment with inclisiran.

Heterozygous or Homozygous Familial Hypercholesterolemia
Phase3
Recruiting
154
Feb 10, 2023
Jun 30, 2028
All
12 Years - (Child, Adult, Older Adult)

Interventions

Drug

Inclisiran

Inclisiran sodium 300mg (equivalent to 284mg inclisiran*) in 1.5mL solution administered subcutaneously in pre-filled syringe

Eligibility Criteria

Key inclusion:

- Male and female participants with a diagnosis of HeFH or HoFH who completed the
ORION-16 or ORION-13 studies

- Per investigator's clinical judgment, participant derived benefit from treatment
with inclisiran in the ORION-16 or ORION-13 studies

Key exclusion:

- Participants who in the feeder inclisiran ORION-16 and ORION-13 studies either
screen failed or permanently discontinued from the treatment/study for any reason or
had serious safety or tolerability issues related to inclisiran treatment

- Any uncontrolled or serious disease, or any medical, physical, or surgical
condition, that may either interfere with participation in the clinical study or
interpretation of clinical study results, and/or put the participant at significant
risk

Novartis Investigative Site

Recruiting

Fortaleza,Ceara,60430275,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,04023-900,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,05403 000,Brazil

Novartis Investigative Site

Recruiting

Toulouse Cedex,31059,France

Novartis Investigative Site

Recruiting

Athens,115 27,Greece

Novartis Investigative Site

Recruiting

Ramat Gan,52621,Israel

Novartis Investigative Site

Recruiting

Jerusalem,9112001,Israel

Novartis Investigative Site

Recruiting

Modena,MO,41124,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00165,Italy

Novartis Investigative Site

Recruiting

Ashrafieh,166830,Lebanon

Novartis Investigative Site

Recruiting

Rotterdam,Zuid Holland,3015 gd,Netherlands

Novartis Investigative Site

Recruiting

Amsterdam,1105 az,Netherlands

Novartis Investigative Site

Recruiting

Oslo,0514,Norway

Novartis Investigative Site

Recruiting

Gdansk,80 952,Poland

Novartis Investigative Site

Recruiting

Ljubljana,1000,Slovenia

Novartis Investigative Site

Recruiting

Bloemfontein,Free State,9301,South Africa

Novartis Investigative Site

Recruiting

Cape Town,Western Cape,7130,South Africa

Novartis Investigative Site

Recruiting

Pamplona,Navarra,31008,Spain

Novartis Investigative Site

Recruiting

A Coruna,15001,Spain

Novartis Investigative Site

Recruiting

Cordoba,Andalucia,14004,Spain

Novartis Investigative Site

Recruiting

Oviedo,Asturias,33011,Spain

Novartis Investigative Site

Recruiting

Geneve 14,1211,Switzerland

Novartis Investigative Site

Recruiting

Adana,01330,Turkey

Novartis Investigative Site

Recruiting

Ankara,06500,Turkey

Novartis Investigative Site

Recruiting

Middlesex,Ub9 6jh,United Kingdom

Excel Medical Clinical Trials LLC

Recruiting

Boca Raton,Florida,33434,United States

Emilio Vega
Seth J Baum

Cincinnati Childrens Hospital MC .

Recruiting

Cincinnati,Ohio,45229-3039,United States

Amy Shah
Bliss Magella

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals